Connective Tissue-Activating Peptide III: A Novel Blood Biomarker for Early Lung Cancer Detection
- 10 June 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (17), 2787-2792
- https://doi.org/10.1200/jco.2008.19.4233
Abstract
Purpose: There are no reliable blood biomarkers to detect early lung cancer. We used a novel strategy that allows discovery of differentially present proteins against a complex and variable background. Methods: Mass spectrometry analyses of paired pulmonary venous-radial arterial blood from 16 lung cancer patients were applied to identify plasma proteins potentially derived from the tumor microenvironment. Two differentially expressed proteins were confirmed in 64 paired venous-arterial blood samples using an immunoassay. Twenty-eight pre- and postsurgical resection peripheral blood samples and two independent, blinded sets of plasma from 149 participants in a lung cancer screening study (49 lung cancers and 100 controls) and 266 participants from the National Heart Lung and Blood Institute Lung Health Study (45 lung cancer and 221 matched controls) determined the accuracy of the two protein markers to detect subclinical lung cancer. Results: Connective tissue-activating peptide III (CTAP III)/ neutrophil activating protein-2 (NAP-2) and haptoglobin were identified to be significantly higher in venous than in arterial blood. CTAP III/NAP-2 levels decreased after tumor resection (P = .01). In two independent population cohorts, CTAP III/NAP-2 was significantly associated with lung cancer and improved the accuracy of a lung cancer risk prediction model that included age, smoking, lung function (FEV1), and an interaction term between FEV1 and CTAP III/NAP-2 (area under the curve, 0.84; 95% CI, 0.77 to 0.91) compared to CAPIII/NAP-2 alone. Conclusion: We identified CTAP III/NAP-2 as a novel biomarker to detect preclinical lung cancer. The study underscores the importance of applying blood biomarkers as part of a multimodal lung cancer risk prediction model instead of as stand-alone tests.Keywords
This publication has 38 references indexed in Scilit:
- Identification of Secreted Proteins that Mediate Cell-Cell Interactions in an In vitro Model of the Lung Cancer MicroenvironmentCancer Research, 2008
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Survival of Patients with Stage I Lung Cancer Detected on CT ScreeningThe New England Journal of Medicine, 2006
- C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary diseaseThorax, 2006
- Protein biomarker discovery and validation: the long and uncertain path to clinical utilityNature Biotechnology, 2006
- Monocyte-derived CXCL7 peptides in the marrow microenvironmentBlood, 2006
- Cancer CXC chemokine networks and tumour angiogenesisEuropean Journal Of Cancer, 2006
- Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysisThorax, 2005
- CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 are Heparin/Heparan Sulfate-degrading EnzymesPublished by Elsevier BV ,1995
- A general cardiovascular risk profile: The Framingham studyThe American Journal of Cardiology, 1976